Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 19k
8 July 2019
Question for written answer E-002161-19
to the Commission
Rule 130
Esther de Lange (PPE)

 Subject:  Dependent position of the medicine production chain
 Answer in writing 

In recent years, Europe has faced shortages of medicines(1), and more producers of raw materials for them have relocated their operations, inter alia, to China and India(2).

The dependence of medicine producers on supplies from outside Europe raises questions about the resilience and security of supply of the European medicines market.

1. Is the Commission aware that, in the case of some antibiotics, only a few factories remain which produce the requisite active substances in Europe? If so, does the Commission also consider that this makes medicine production very vulnerable and that the limited production of raw materials in the EU is undesirable?

2. What practical measures will the Commission take to address this issue?


Original language of question: NL 
Last updated: 26 July 2019Legal notice